Ann Coloproctol.  2019 Oct;35(5):254-261. 10.3393/ac.2018.12.04.

Indication for and Effect of Adjuvant Chemotherapy for Stage IIa (T3N0M0) Colon Cancer

Affiliations
  • 1Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. cmcgslee@catholic.ac.kr

Abstract

PURPOSE
The efficacy of adjuvant chemotherapy (AC) in stage IIa colon cancer is controversial. This study aimed to investigate the factors influencing survival in patients with stage IIa colon cancer, the role of AC, and the indications for AC utilization by surgical oncologists.
METHODS
Between January 2004 and December 2010, 736 patients with stage IIa colon cancer underwent curative resection in 1 of 6 participating hospitals. Factors related to survival were identified and analyzed according to whether AC was administered or not. After high- and low-risk groups were identified, their respective results were analyzed.
RESULTS
The 5-year overall survival (OS) of stage IIa colon cancer was 90.3%. With the exception of poorly differentiated histology, indications for AC did not include typical high-risk factors. The indications for AC were significantly younger patients, higher body mass index (BMI), lower American Society of Anesthesiologists (ASA) physical status classification, and higher histologic grade. BMI, preoperative carcinoembryonic antigen, and harvested lymph node (LN) count were significant factors for disease-free survival, while BMI and ASA physical status classification were significant factors for OS in the chemotherapy group. In the high-risk group, AC was associated with increased OS in univariate analysis. BMI and harvested LN count were statistically significant in multivariate analysis.
CONCLUSION
Surgical oncologists consider the patient's condition and postoperative course rather than high-risk factors to determine use of AC. Regardless of AC use, both the extent of surgery and the patient's subsequent status affected the survival rate in the high-risk group. None of the factors identified influenced survival rate in the low-risk group.

Keyword

Chemotherapy; Colonic neoplasms; Surgeons

MeSH Terms

Body Mass Index
Carcinoembryonic Antigen
Chemotherapy, Adjuvant*
Classification
Colon*
Colonic Neoplasms*
Disease-Free Survival
Drug Therapy
Humans
Lymph Nodes
Multivariate Analysis
Surgeons
Survival Rate
Carcinoembryonic Antigen
Full Text Links
  • AC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr